MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value
Portfolio Pulse from
MeiraGTx Holdings plc is advancing its gene therapy pipeline with potential near-term BLA filings. AAV-AIPL1 for Leber congenital amaurosis 4 may soon file in the UK, while Bota-vec, developed with Janssen, targets a 2025 filing for X-linked Retinitis Pigmentosa. A phase 3 study for AAV-GAD in Parkinson's Disease is also expected in 2025.
January 22, 2025 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MeiraGTx Holdings plc is progressing with potential BLA filings for its gene therapies, which could significantly enhance shareholder value. AAV-AIPL1 may file in the UK soon, and Bota-vec, in collaboration with Janssen, targets a 2025 filing.
The potential BLA filings for AAV-AIPL1 and Bota-vec represent significant milestones for MeiraGTx, likely to boost investor confidence and shareholder value. The collaboration with Janssen further strengthens the company's position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100